Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SSGJ-627 in moderate to severe active ulcerative colitis
CTR20260817Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSGJ-627 in autoimmune colitis, sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Safety endpoint. Started May 2026; status: active.
02
Drugs
SSGJ-627
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20260817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260817.